Rocatinlimab + Placebo

Phase 3Active

1 views this week 0 watching⚡ Active

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Prurigo Nodularis

Conditions

Prurigo Nodularis

Trial Timeline

Jul 18, 2024 → Jan 17, 2027

NCT ID

NCT06527404

About Rocatinlimab + Placebo

Rocatinlimab + Placebo is a phase 3 stage product being developed by Amgen for Prurigo Nodularis. The current trial status is active. This product is registered under clinical trial identifier NCT06527404. Target conditions include Prurigo Nodularis.

What happened to similar drugs?

1 of 6 similar drugs in Prurigo Nodularis were approved

Approved (1) Terminated (0) Active (5)

✅UpadacitinibAbbVieApproved

🔄DupilumabSanofiPhase 3

🔄Ruxolitinib Cream + Vehicle CreamIncytePhase 3

🔄Povorcitinib + PlaceboIncytePhase 3

🔄Ruxolitinib Cream + Vehicle CreamIncytePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06527404	Phase 3	Active	Jul 18, 2024	Jan 17, 2027	Prurigo Nodularis
NCT06376045	Phase 2	Active	May 24, 2024	Dec 11, 2026	Asthma
NCT05899816	Phase 3	Completed	Jun 7, 2023	Nov 14, 2024	Atopic Dermatitis
NCT05704738	Phase 3	Completed	Apr 20, 2023	Nov 25, 2025	Atopic Dermatitis
NCT05398445	Phase 3	Completed	May 31, 2022	Jan 13, 2025	Atopic Dermatitis

Competing Products

20 competing products in Prurigo Nodularis

See all competitors

Product	Company	Stage	Hype Score
Vixarelimab + Placebo	Kiniksa Pharmaceuticals	Phase 2	29
Upadacitinib	AbbVie	Approved	50
Pimecrolimus + Hydrocortisone + Pimecrolimus	Novartis	Phase 2	35
Abrocitinib	Pfizer	Phase 2	35
Dupilumab SAR231893 (REGN668)	Sanofi	Pre-clinical	33
Dupilumab	Sanofi	Phase 3	47
Dupilumab	Sanofi	Pre-clinical	33
Dupilumab	Sanofi	Pre-clinical	30
Ruxolitinib Cream 1.5%	Incyte	Phase 1	26
Ruxolitinib Cream + Vehicle Cream	Incyte	Phase 3	37
INCB054707 + Placebo	Incyte	Phase 2	32
Povorcitinib + Placebo	Incyte	Phase 3	44
Povorcitinib + Placebo	Incyte	Phase 3	44
Ruxolitinib Cream + Vehicle Cream	Incyte	Phase 3	37
CDX-0159 + Normal saline	Celldex Therapeutics	Phase 1	23
barzolvolimab	Celldex Therapeutics	Phase 2	33
nalbuphine HCl ER tablets 90 mg BID + nalbuphine HCl ER tablets 180 mg BID + Placebo tablets BID	Trevi Therapeutics	Phase 2/3	32
nalbuphine HCl ER	Trevi Therapeutics	Phase 2/3	32
Nalbuphine ER Tablets + Placebo Tablets	Trevi Therapeutics	Phase 2/3	32
serlopitant + Placebo	Vyne Therapeutics	Phase 2	25